InvestorBrandNetwork (IBN) Content Platform

Serious investors — and anyone concerned with protecting and building wealth in volatile times — invited to attend the New Orleans Investment Conference to be held in New Orleans, November 1-4, 2023.

With a rich legacy spanning almost 50 years, the New Orleans Investment Conference has been acclaimed as “The Greatest Investment Show on Earth” by Money Magazine. Held in the heart of New Orleans, the 2023 Conference is set to present a dream team of world-class experts on…

Read More>>

To learn more, please visit https://ibn.fm/ISvQC

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

PowerTap Hydrogen Capital (NEO: MOVE) (OTC: MOTNF), a leading provider of onsite hydrogen production technology, is sharing a status update regarding the management cease trade order (“MCTO”) granted on Sept. 29, 2023, by the British Columbia Securities Commission. The update noted that last month the company had announced that there would be a delay in the filing of its financial statements and accompanying management discussion and analysis for the fiscal year ended June 30, 2023; as a result, the MCTO had been issued. According to the status update, during the MCTO, while the company’s CEO and CFO will not be able to trade in the company’s common shares, the general investing public may do so.

PowerTap is also reporting that SHIM & Associates LLP has notified the company that it is no longer in a position to continue the audit of the consolidated financial statements of the company due to scheduling conflicts. The announcement noted that there are no disagreements, consultations or unresolved issues in connection with the resignation of SHIM, which has been approved by PowerTap’s board of directors. The company is now in the process of identifying a successor auditor and will provide a further update on or before Oct. 27, 2023.

To view the full press release, visit https://ibn.fm/T55yC

About PowerTap Hydrogen Capital Corp.

PowerTap Hydrogen, through its wholly owned subsidiary PowerTap Hydrogen Fueling Corp., is focused on installing hydrogen production and dispensing fueling infrastructure in the United States. PowerTap’s patented solution has been developed over 20 years. PowerTap is now commercializing its third-generation blue hydrogen product that will focus on the refueling needs of the automotive and long-haul trucking markets that lack hydrogen fueling infrastructure. For more information about the company, please visit www.PowerTapCapital.com.

NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on the results of its annual and special meeting of shareholders, which was held Oct. 12, 2023. According to the announcement, 66 shareholders attended the meeting, either in person or by proxy; those shareholders held 91,903,025 common shares, or 39.16% of Cybin’s total issued and outstanding common shares. During the meetings, shareholders approved the proposed acquisition of Small Pharma Inc., according to the conditions outlined in the Aug. 28, 2023, acquisition agreement. In addition, the appointment of Zeifmans LLP as official auditor for the company until the next annual meeting of shareholders was approved, as was a special resolution to set the number of directors for the company at six. Finally, shareholders elected the company directors that were nominated in Cybin’s management information circular; those directors include Theresa Firestone, Grant Froese, Paul Glavine, Eric Hoskins, Mark Lawson and Eric So.

To view the full press release, visit https://ibn.fm/pHddL

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental-health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug-discovery platforms, innovative drug-delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder; the company also has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

• GolfLync’s members embrace innovative features, including organizing tee times, sharing golf experiences, hosting events, and building lasting connections with like-minded enthusiasts
• The GolfLync app facilitates connections based on location and personal preferences on the course – making tee times more enjoyable and easier to facilitate
• The global golf club market is expected to grow at a CAGR of 2.5%, resulting in a value of $4.45 billion by 2027

GolfLync, one of the hottest and fastest-growing social networking platforms for golf enthusiasts, has announced that enrollment has surpassed 75,000 members across the United States. This monumental growth underscores the company’s mission and ability to unite golfers, creating dynamic golfing communities that continue to thrive. GolfLync’s revolutionary Virtual Golf Clubs(TM) (“VGCs”) have reshaped how golfers engage, share experiences, and bring together like-minded individuals to share experiences and the love of the sport (GolfLync Surpasses 75,000 Members Nationwide and Hosts Members in Over 700 Private and Public Virtual Golf Clubs(TM)).

From local golf clubs to large national networks, GolfLync members are embracing the platform’s abilities – featuring innovative features with private and public VCGs as the epicenter for organizing tee times, sharing golf experiences, hosting events, and building lasting…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

• SenesTech pioneered an innovative rat control method that restricts the fertility of both male and female rats, ContraPest(R)
• With cities around the country and the world, in general, implementing a raft of rat control methods, SenesTech is eager to work with city governments to address the rat crises
• Rat populations are surging in many major cities, driven by the post-COVID rebound in business and climate change
• Studies show that ContraPest can reduce rat populations by more than 90% and sustain the reduced numbers, when added to an integrated pest management plan

Once threatened by the sudden COVID-induced closure of businesses and restaurants, which forced rats to adapt by moving to residential areas in search of food or die – renowned rodentologist Bobby Corrigan estimates that hundreds of thousands, if not millions, died – the long-tailed rodents are now seemingly enjoying a change of fortune. Rat populations are surging in many major cities, driven by the post-COVID rebound in restaurant operations and the reopening of businesses, which are providing alternative and ample locations where the rodents find food. Moreover, “Climate change has brought longer stretches of warmer weather, which means more time for breeding,” explains an article in PBS (https://ibn.fm/Pqceu).

This is concerning. Rats cause billions of dollars in damages annually worldwide and carry harmful and sometimes deadly diseases. Thus, to avert a crisis, cities have moved to control the vermin, turning their attention toward addressing the trash problem as one of their…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, has announced the release of the latest episode of its Stock2Me Podcast. The episode features financial writer and journalist M.E. Tuthill, who authored “Repo-Madness: A Simpleton’s Guide to the Street’s Wicked Ways,” a book about the shadow banking system. The Stock2Me Podcast spotlights companies and individuals who are actively revolutionizing age-old business practices within their respective markets.

During the interview, Tuthill shared her background as a radio journalist turned financial advisor who ultimately landed in her current career as a financial writer. “I got a position as a financial writer at iMoneyNet,” said financial writer and journalist M.E. Tuthill during the podcast. “I wrote articles about money market funds. When I first got the job, I thought, ‘Oh, this is great. I’ve got a 9-to-5 and a steady paycheck,’ but money market funds weren’t really that exciting to write about. When the financial crisis hit, everything changed. Those funds had such an integral role in what happened. For the next nine years after that happened, I wrote every week and every day about the money market funds and the shadow banking system in general. I got addicted to it; I got hooked on it.”

To listen to the full interview, visit https://ibn.fm/FhpA9

To view the full press release, visit https://ibn.fm/TttHL

About InvestorBrandNetwork

The InvestorBrandNetwork consists of financial brands introduced to the investment public over the course of more than 15 years. IBN has amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand its branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve its increasingly diversified list of clients. For more information on IBN, visit www.investorbrandnetwork.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Splash Beverage (NYSE American: SBEV), a portfolio company of leading beverage brands, announced that its Copa di Vino wine brand will be featured by convenience store retailing giant Circle K in more than 130 locations scattered throughout Alabama and Florida. The company said the coverage will include four varieties of the premium single-serve wine and should be available starting this month. Circle K was founded in 1951 and, after being acquired by Canadian-based Alimentation Couche-Tard in 2003, has grown into one of the most widely recognized convenience store brands.

“This important authorization is another successful result of the hard work of the Splash team in building a distribution network capable of serving national chains,” said Splash Beverage CEO and chair Robert Nistico in the press release. “Working with our valued distribution partner Gulf Distributing, we were able to earn this opportunity with Circle K. More product on shelf in front of more consumers, equals more revenue.  We will take this and the success on the West Coast and continue to add visibility of our brands with this keystone retailer in their other divisions.”

To view the full press release, visit https://ibn.fm/LalZF

About Splash Beverage Group Inc.

Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and nonalcoholic beverage brands including Copa di Vino wines by the glass, SALT flavored tequilas, Pulpoloco sangrias, and TapouT performance hydration and recovery drinks. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution. For more information about the company, please visit www.SplashBeverageGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Red White & Bloom (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, is providing a status update regarding Aleafia Health Inc., announcing that RWBYF has been selected as the successful bidder under the sale and investment solicitation process (“SISP”). The selection was approved by the Ontario Superior Court of Justice in connection with the proceedings of Aleafia and certain subsidiaries under the Companies’ Creditors Arrangement Act (“CCAA”). The announcement noted that in August 2023, the court had approved the terms of a SISP, including a stalking horse asset purchase and share subscription agreement noting that RWB would acquire certain assets from Aleafia Health and subscribe for shares of certain subsidiaries of Aleafia Health.

The stalking horse agreement outlines provisions for a reverse vesting transaction involving a wholly owned subsidiary of RWB that would subscribe for shares of certain of Aleafia Health’s subsidiaries and acquire specific intellectual property owned, licensed or leased by Aleafia Health. After closing, RWB’s subsidiary would be the sole shareholder of these specific properties. An approval order hearing date has been set for Oct. 27, 2023, and if the approval order is issued, Red White & Bloom expects to close the transaction no later than Nov. 22, 2023.

To view the full press release, visit https://ibn.fm/R8okF

About Red White & Bloom Brands Inc.

Red White & Bloom is a multistate cannabis operator and house of premium brands in the U.S. legal cannabis sector. RWB is predominantly focusing its investments on the major U.S. markets, including Arizona, California, Florida, Massachusetts, Missouri and Michigan. For more information about the company, please visit www.RedWhiteBloom.com.

NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing-related sleep conditions arising from certain dentofacial abnormalities, is spotlighted in a recent Proactive feature interview. During the interview, Vivos Therapeutics CEO Kirk Huntsman chats with Proactive host Steve Darling about recent company news, including an exclusive distribution agreement Vivos just signed with Dubai-based NOUM DMCC (“NOUM DMCC”). NOUM is focused on diagnostic testing and the distribution of treatment products for healthcare providers and hospital networks specializing in obstructive sleep apnea (“OSA”) patients across the Middle East-North Africa (“MENA”) region.

During the interview, Huntsman explained the significance of this partnership and how it addresses the growing demand for effective treatment alternatives to Continuous Positive Airway Pressure (“CPAP”) for individuals suffering from OSA. According to the agreement, Vivos has granted NOUM exclusive distribution rights for its innovative products and services in several key MENA countries, including Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, Oman, Jordan, Lebanon and Palestine. In addition, NOUM will promptly initiate the process of seeking regulatory approvals for Vivos’ medical devices within these countries, with anticipated approval timelines varying from a few weeks to several months. Huntsman also noted that the company’s flagship daytime-nighttime appliance is slated to undergo a clinical trial at Stanford Medicine, with participant enrollment scheduled to begin early 2024. The trial is a milestone for Vivos because it could validate the efficacy of the company’s proprietary appliance in addressing OSA.

To view the full interview, visit https://ibn.fm/M37Zo

To view the full press release, visit https://ibn.fm/zbzpa

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The Vivos Method represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild to moderate OSA. It has proven effective in the treatment of more than 40,000 patients worldwide by more than 1,800 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos Method. For more information about this company, visit www.Vivos.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has closed its previously announced private placement of unsecured convertible debentures to Jason Carroll, Tryp’s newly appointed CEO.

The private placement was for gross proceeds of AUD$175,000. Tryp anticipates using the funds to advance its R&D programs and for general working capital purposes. According to the announcement, securities issued as part of the private placement, including the common shares issuable on conversion of the debentures, are subject to four-month-plus-one-day hold period in accordance with securities laws.

To view the full release, visit https://ibn.fm/KS032

About Tryp Therapeutics Inc.

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The company has initiated a phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, where an interim analysis showed an average reduction in binge eating episodes of greater than 80%. The company is also planning for phase 2a clinical trials with the University of Michigan for the treatment of fibromyalgia and with Massachusetts General Hospital for the treatment of abdominal pain related to irritable bowel syndrome. An IND for both of these trials has been cleared by the FDA to proceed. Each of the studies are utilizing TRP-8802 (synthetic oral psilocybin) to demonstrate efficacy in these indications. Where a preliminary clinical benefit is demonstrated, subsequent studies are expected to utilize TRP-8803 (IV-infused psilocin), which has the potential to further improve efficacy, safety and patient experience. For more information about the company, please visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Large, mid-size, and small pharma companies, are invited to attend the 18th Biopharma Drug Discovery Nexus being held October 17-18, 2023, in Philadelphia. As the countdown for this prestigious event begins, the world is set to witness the innovative benchmarks in the realm of life sciences and drug discovery. The 18th edition of this event will serve as an incredible platform for advanced technologies, groundbreaking research, and collaborative discussions.

The BioPharma Drug Discovery Nexus has long been synonymous with technological advancement in the life sciences industry. The popular event will bring together specialists and thought leaders from across the pharmaceutical and biotechnology sectors. Attendees have a great opportunity to meet important…

Read More>>

To learn more, please visit https://ibn.fm/ZTuDI.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

CISO Global Inc. (NASDAQ: CISO), an industry leader as a managed cybersecurity and compliance provider, has been listed on PCI Marketplace as a PCI Quality Security Assessor (“QSA”). The distinction means that CISO Global is certified and authorized by the Payment Card Industry Security Standards Council (“PCI SSC”) to assess and validate the compliance of organizations with Payment Card Industry Data Security Standard (“PCI DSS”). PCI DSS is a set of security standards that works to protect the confidentiality and integrity of credit-card and payment-card data. CISO Global works with clients to assist them as they transition to upcoming PCI 4.0 standards, performing security assessments to verify PCI DSS compliance.

The company has expanded its team of PCI assessors to meet growing client needs as organizations start on the process of becoming compliant with the “heftier” requirements. CISO Global provides several levels of services that include On-site Assessment and Remediation Services, PCI Gap Assessment Services and External PCI ASV Scanning Service, as well as Governance, Risk and Compliance (GRC) Tracking. “We are committed to helping the industry meet the increasing list of regulatory requirements as seamlessly as possible,” said CISO Global CEO David Jemmett in the press release. “Our teams are focused on meeting these soon-to-be critical requirements for increased standards and practices to secure credit card data and better protect merchants and their customers so they can continue to operate their businesses without interruption.”

To view the full press release, visit https://ibn.fm/nOOJ0

About CISO Global Inc.

CISO Global is an industry leader as a managed cybersecurity and compliance provider. The company is rapidly expanding by acquiring world-class cybersecurity, secured managed services and compliance companies with top-tier talent that utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations against continuing and emerging security threats and compliance obligations. For more information about the company, visit www.CISO.inc.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a human factor study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (“PTSD”). According to the announcement, the study will evaluate the human factor interface and usability of SPC-15’s intranasal formulation in combination with a nose-to-brain delivery mechanism. “The human factor study is an important step as we prepare and plan to enter the clinic with SPC-15 for the treatment of PTSD and stress-related disorders,” said Eric Weisblum, chief executive officer of Silo Pharma. “The first of the two-part study was launched in October, with the expected completion of this study before year end 2023.”

To view the full press release, visit https://ibn.fm/lU0vE

About Silo Pharma Inc.

Silo Pharma is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which it believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company today announced that its flagship daytime-nighttime appliance (“DNA”) will be tested in a clinical trial at Stanford Medicine. According to the update, the protocol has been finalized and participant enrollment will begin in early 2024. “In a retrospective review of 220 patients*, we have seen that Vivos’ oral appliance therapy decreases the apnea-hypopnea index (‘AHI’) while increasing airway volume. The median reduction in AHI was 49% in this cohort and a quarter of patients resolved their OSA completely. These end results were measured after a 12-18 month course of therapy without the appliance in the mouth – meaning the effects persisted while not using treatment – something not seen with CPAP,” said Cecilia Wu MD, co-chair of the clinical advisory board at Vivos Therapeutics. “While Vivos believes in these results, it is important to apply the highest standards in medical research in the form of a prospective randomized controlled trial. This will truly test Vivos’ treatment to the same standard as all other modalities.”

To view the full press release, visit https://ibn.fm/eV3xk

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild-to-moderate OSA. It has proven effective in approximately 40,000 patients treated worldwide by more than 1,800 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and/or palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using The Vivos Method. For more information, visit www.Vivos.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

*Katz D, Demaria S, Heckman S, Lin F, Kushida C. Use of the Complete Airway Repositioning and Expansion (CARE) approach in 220 patients with Obstructive Sleep Apnea (OSA): A retrospective cohort study. Sleep Med. 2022 Nov;99:18-22.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Zevra Therapeutics (NASDAQ GS: ZVRA), a rare-disease therapeutics company, has named Neil F. McFarlane as president and CEO; McFarlane will also serve on the company’s board of directors. The new appointments are effective immediately. According to the announcement, Christal M.M. Mickle, who has been serving as interim CEO and president since June, will continue serving in her role as chief development officer. A former officer and enlisted soldier in the United States Army Reserves, McFarlane has an impressive, results-driven track record as a biopharmaceutical leader with proven ability to accelerate Zevra’s strategy of melding science, data and patient needs to create transformational therapies for patients with rare diseases. Throughout his two-decade-plus career, he has delivered sustained growth in a range of specialty and rare-disease products around the world, including the United States, Europe, Asia and Latin America. Most recently, he served as CEO and board member at Adamas Pharmaceuticals Inc. He has also worked at Retrophin Inc. (now Travere Therapeutics, Inc.), UCB Inc., Genzyme Corporation (now Sanofi) and Sangstat Medical Corporation (acquired by Genzyme). Zevra also announced the effectiveness of Joseph B. Saluri’s retirement from the board of directors.

“Neil’s appointment as president and chief executive officer is the culmination of a thorough process undertaken by the board of directors and comes at a pivotal time for our company,” said Zevra Therapeutics board chair Tamara A. (Seymour) Favorito in the press release. “His successful track record of leading innovative companies through periods of strategic change, and enhancing value to patients, employees and shareholders will be of tremendous importance to Zevra as we deliver much-needed therapies to the rare-disease community. We have great confidence in his ability to shepherd our company through the next phase of our journey. In addition, we appreciate Christal’s contributions to Zevra during this important time and look forward to her continued contributions. We also extend our sincere gratitude to Joe Saluri for his significant contributions to the company as a board member. He has played an integral part in advancing the company’s mission and bringing valuable expertise throughout its entire existence as a public company.”

To view the full press release, visit https://ibn.fm/knMD3

About Zevra Therapeutics

Zevra Therapeutics is a rare-disease company melding science, data and patient need to create transformational therapies for diseases with limited or no treatment options. With unique, data-driven clinical, regulatory and commercialization strategies, the company is overcoming complex drug-development challenges to bring much-needed therapies to patients. With both regulatory and clinical stage product candidates, Zevra Therapeutics is building its commercial capability to make new therapies available to the rare disease community. For more information about the company, please visit www.Zevra.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Safety Shot (NASDAQ: SHOT) today announced that Jarrett Boon, who has served as the company’s chief operating officer since August 2023, has been appointed to Safety Shot’s board of directors. Boon is leading the launch and growth of the company’s Safety Shot functional drink business this quarter. Boon was the co-founder and CEO of GBB Drink Lab, which developed Safety Shot, the first patented beverage that helps people feel better faster by reducing blood alcohol content and boosting clarity. “In the past few months since I’ve joined the company, our outstanding team has teed up the Safety Shot drink for launch this last quarter of 2023 and built market momentum for direct-to-consumer sales,” said Safety Shot’s COO Jarrett Boon. “I couldn’t be more excited about the potential for Safety Shot to improve health and wellbeing for consumers. I’m pleased to become a member of the board to guide our corporate direction and deliver solid results for all our stakeholders including Safety Shot shareholders.”

To view the full press release, visit https://ibn.fm/hah3n

About Safety Shot Inc.

Safety Shot, a wellness and functional beverage company, is set to launch Safety Shot the last quarter of 2023, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting brain clarity. Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://jupiterwellness.com/email-alerts.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Pressure BioSciences (OTCQB: PBIO) (“PBI”) is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and specialty process development and testing services to the global pharmaceuticals, nutraceuticals, cosmeceuticals, food/beverage and other industries. The company today announced the award of the first Canadian patent for its revolutionary UltraShear(TM) Technology (“UltraShear(TM)” or “USTTM”) platform. “Nanoemulsions have long been shown to exhibit improved absorption, higher bioavailability and greater stability, while often requiring lower levels of emulsifiers than macro/micro emulsion products,” said Dr. Edmund Y. Ting, SVP of Engineering of PBI and the inventor on this patent. “Because of these significant advantages, nanoemulsions are currently the focus of numerous research efforts worldwide. However, cost-effective scale-up of high quality nanoemulsion processing at a commercial level has long remained to be quite challenging. Importantly, we believe that PBI’s innovative, patented and now Canadian patent-protected UltraShear platform will provide the pivotal key to commercial success for nanoemulsion products.”

To view the full press release, visit https://ibn.fm/ae9Hm

About Pressure BioSciences Inc.

Pressure BioSciences is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Its products utilize both constant and alternating pressure. The company’s patented enabling technology platform, Pressure Cycling Technology (“PCT”), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterrorism applications. The company has recently expanded its market opportunities with the acquisition of the BaroFold(TM) patented technology platform, allowing it to enter the bio-pharma contract services and GMP manufacturing equipment sector. The company has also developed the scalable and high-efficiency pressure-based UltraShear Technology(TM) (UltraShear(TM)) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. The company’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to its customers. For more information about the company, visit www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Splash Beverage (NYSE American: SBEV), a portfolio company of leading beverage brands, has entered into a new agreement with Georgia-based Horizon Retailers Association (“HRA”). One of the South’s fastest-growing convenience store retail associations, HRS represents more than 2,500 retailers and 20 major vendors in the Southeast United States. According to the announcement, HRA is adding SBEV’s TapouT Energy Drink to its fall planogram, which is available to all participating stores, and will include three “facings” in its Energy Drink category, one for each TapouT flavor. SBEV noted that this new agreement with HRA is a direct result of its recently signed distribution agreement with United Distributors of Georgia.

“We couldn’t be prouder to announce this agreement,” said Splash Beverage CEO Robert Nistico in the press release. “This is our largest planogramed authorization to date, and [we] believe TapouT Energy Drink will greatly benefit from this level of retail concentration and cold availability for immediate consumption. Our team has been hard at work over the past few months putting all these pieces into place. Splash’s footprint will increase significantly in the southeast with this announcement. This is exciting news as we continue to execute on our distribution and retail strategy. As I discussed a few months ago, this process takes time. We push for distribution, support those efforts with marketing, then start pushing again for more distribution coverage ultimately achieving greater and greater availability.”

To view the full press release, visit https://ibn.fm/M9PbQ

About Splash Beverage Group Inc.

Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and nonalcoholic beverage brands including Copa di Vino wines by the glass, SALT flavored tequilas, Pulpoloco sangrias, and TapouT performance hydration and recovery drinks. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution. For more information about the company, please visit www.SplashBeverageGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Amesite (NASDAQ: AMST), a leading artificial intelligence software company, is expanding its partnership with Michigan Works! Southeast (“MWSE”). According to the announcement, the partnership will result in the launch of 12 new courses this year. The courses will provide training on artificial intelligence technologies and their applications in the modern workplace. These courses will be found on MWSE’s proprietary Learning Community Environment(R) , which is powered by Amesite. Amesite noted that the new courses provide a deep dive into the transformative wave of Industry 4.0 and include modules focused on an array of pertinent topics, including the underpinnings of internet technology, challenges posed by AI in job retention and the innovative use of ChatGPT.

There are even modules that teach students how to write compelling resumes, cover letters and follow-up emails as well as interview strategies and how to optimize their online job search. Noting the increase of “new-collar” jobs, an MWSE official observed that the goal of the stronger partnership is to equip community members with the requisite skills for those roles and prepare them for the evolving job landscape of Industry 4.0. “Workforce development agencies have a significant opportunity to leverage modern tools to assist individuals in their growth and readiness for the job market, and we are excited to be able to provide critical skills to a multi-billion-dollar market and expect these offerings to be in high demand,” said Amesite founder & CEO Dr. Ann Marie Sastry in the press release. “At Amesite, we’ve focused on creating solutions that easily integrate into existing systems. Our partnership with Microsoft enables us to deploy these tools swiftly, often within a 24-hour window.

To view the full press release, visit https://ibn.fm/OtFRH

About Amesite Inc.

Amesite delivers its scalable, customizable, white-labeled online learning platform to universities, businesses, museums and government agencies, enabling them to deliver outstanding digital learning. Amesite provides a single system that combines eCommerce, instruction, engagement, analytics and administration using best-in-class infrastructure to serve multibillion-dollar online learning markets. For more information about the company, please visit www.Amesite.io.

NOTE TO INVESTORS: The latest news and updates relating to AMST are available in the company’s newsroom at https://ibn.fm/AMST

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Standard Lithium (TSX.V: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial lithium company, today announced that, to the best of its knowledge, it has drilled and sampled a new highest confirmed lithium grade brine in North America, with a grade of 663 mg/L lithium. According to the update, the results reflect lithium sample analyses from a newly drilled well from the company’s significant expansion work in the East Texas Smackover region. “We continue to be very excited by the quality and scale of the lithium brine assets we’re adding in East Texas,” said Dr. Andy Robinson, president and COO of Standard Lithium. “The lithium sample analysis from a newly-drilled well delivered, to the best of our knowledge, a new highest-grade lithium brine concentration in North America and confirmed that we are securing the highest-grade lithium brine resource outside of Chile and Argentina. We continue to expand our footprint in the East Texas Smackover and de-risk the opportunity with additional drilling, sampling and definition work.”

To view the full press release, visit https://ibn.fm/mosAL

About Standard Lithium Ltd.

Standard Lithium is a leading near-commercial lithium development company focused on the sustainable development of a portfolio of lithium-brine bearing properties in the United States. The company prioritizes brine projects characterized by high-grade resources, robust infrastructure, skilled labor, and streamlined permitting. The company aims to achieve sustainable, commercial-scale lithium production via the application of a scalable and fully integrated direct lithium extraction (“DLE”) and purification process. The company’s flagship projects, the Phase 1A and the South West Arkansas projects, are located on the Smackover Formation in southern Arkansas near the Louisiana state line, a region with a long-standing and established brine processing industry. The company has also identified a number of highly prospective lithium brine project areas in the Smackover Formation in East Texas and began an extensive brine leasing program in the key project areas. In addition, the company has an interest in certain mineral leases located in the Mojave Desert in San Bernardino County, California. Standard Lithium trades on both the TSX Venture Exchange and the NYSE American under the symbol SLI and on the Frankfurt Stock Exchange under the symbol S5L. For more information, please visit the company’s website at www.StandardLithium.com.

NOTE TO INVESTORS: The latest news and updates relating to SLI are available in the company’s newsroom at https://ibn.fm/SLI

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

SenesTech (NASDAQ: SNES), animal pest fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, will be participating in this month’s Lytham Partners Fall 2023 Investor Conference; the conference is slated for Oct. 17, 2023. According to the announcement, SenesTech CEO Joel Fruendt and CFO Tom Chesterman will present during the elite event. Their presentation is scheduled to begin at 7 a.m. ET. In addition, the two company officials will be available to host one-on-one meetings with investors.

To view the presentation, visit https://ibn.fm/wCnRR or https://ibn.fm/42I3F

To view the full press release, visit https://ibn.fm/Gkucz

About SenesTech Inc.

SenesTech is committed to being “the pest-control difference” for the 21st century. The company’s passion is to create a healthy environment by virtually eliminating rodent pest populations. The company keeps an inescapable truth in mind: two rats and their descendants can be responsible for the birth of up to 15,000 pups after a year. SenesTech invented ContraPest, the only U.S. EPA-registered contraceptive for male and female rats. ContraPest fits seamlessly into all integrated pest-management programs, greatly improving the overall goal of effective rat management. The company strives for clean cities, efficient businesses and happy households — with a product that was designed to be effective and sustainable without killing rats. For more information about the company, please visit www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Mydecine Innovations (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has completed its admission to the Access segment of the AQSE Growth Market; the company begins trading on today at market open. According to the announcement, Mydecine will have a dual listing with its common shares fully fungible through a CREST Depositary Interest (“CDI”); the company will be classified as a healthcare company on the access segment of the Aquis Stock Exchange.

 In the announcement, the company noted that its various families of novel second-generation molecules are showing significant improvements over the first generation of psychedelic treatments. Mydecine is currently working with a preclinical team at the University of Alberta to work these molecules through the Investigational New Drug enabling stage with plants to begin human clinical trials in 2024. Mydecine’s comprehensive intellectual property strategy covers novel molecules, drug formulations, delivery mechanisms and methods of production. “We are incredibly excited to list our securities for trading in the UK on the AQSE Growth Market,” said Mydecine Innovations CEO Josh Bartch in the press release. “We believe Mydecine is at a pivotal phase in its development and look forward to increased exposure to UK and European investors alike.”

To view the full press release, visit https://ibn.fm/WzWJV

About Mydecine Innovations Group Inc.

Mydecine Innovations is a publicly traded, prerevenue biopharmaceutical company that began operations in North America and Europe in early 2020. Mydecine was founded to increase physicians’ access to serotonin-modulating medicine. Recent research has demonstrated the therapeutic potential of psychedelic substances such as psilocybin and MDMA for treating intractable conditions such as pain, anxiety, depression, addiction and PTSD, along with neurodegenerative disorders. Mydecine believes these compounds can be safer, more effective and more accessible for patients and medical professionals through modern drug chemistry paired with artificial intelligence (“AI”). Mydecine is developing innovative medications for target indications with high mortality rates that have lacked innovation for decades and are controlled by dominant corporations. Mydecine developed several prodrug families, beginning with a psilocybin-derived smoking cessation drug  undergoing an NIDA-funded trial at Johns Hopkins University. The company is also developing MYCO-006, short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. Mydecine utilizes cutting-edge AI and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make those medications affordable and accessible to the general public upon Health Canada and FDA approval. The Mydecine team is enthusiastic about its mission and is dedicated to creating a positive difference in the lives of others. For more information about the company, please visit www.Mydecine.com.

NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Siyata Mobile (NASDAQ: SYTA, SYTAW), a global vendor of Push-to-Talk over Cellular (“PoC”) devices and cellular signal booster systems, has been invited to present at Maxim Group LLC’s Exploring All Corners of the Tech Sector conference. The event is scheduled for Oct. 10–11, 2023, and will be live on M-Vest. According to the announcement, during the event, Maxim senior analysts will facilitate engaging dialogues with executives and key team members of a variety of tech-focused companies. “Our company will be taking part in the Virtual Tech Conference Series: Exploring All Corners of the Tech Sector,” stated the company in the press release. “The continuous evolution of technology is paving the way for innovations across all industries, including financial services, esports, iGaming, entertainment and more. In the second installment of the 2023 Virtual Tech Conference, participants will explore how emerging growth companies are leveraging new technologies to position themselves for the future.”

To view the full presentation, visit https://ibn.fm/jeVJI

To view the full press release, visit https://ibn.fm/0DeyF

About Siyata Mobile Inc.

Siyata Mobile is a B2B global vendor of next-generation, Push-to-Talk over cellular handsets and accessories. Its portfolio of rugged PTT handsets and accessories enables first responders and enterprise workers to instantly communicate over a nationwide cellular network of choice, to increase situational awareness and save lives. Police, fire and ambulance organizations as well as schools, utilities, security companies, hospitals, waste-management companies, resorts and many other organizations use Siyata PTT handsets and accessories. In support of Siyata’s Push-to-Talk handsets and accessories, the company also offers enterprise-grade, in-vehicle solutions and cellular booster systems enabling its customers to communicate effectively when they are in their vehicles, even in areas where the cellular signal is weak. Siyata sells its portfolio through leading North American cellular carriers, as well as through international cellular carriers and distributors. For more information about the company, visit www.SiyataMobile.com or www.UnidenCellular.com.

NOTE TO INVESTORS: The latest news and updates relating to SYTA are available in the company’s newsroom at http://ibn.fm/SYTA

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Large, mid-size and small pharma companies are invited to attend the 18th Biopharma Medical Affairs Nexus being held October 17-18, 2023, in Philadelphia. The event will focus on networking and the flow of important data in key areas of Medical Affairs, Medical Operations, Medical Excellence, MSL, Medical Communications, Scientific Affairs, Field Medical, Medical Education, Clinical Investigation, Business Intelligence, and Medical Science.

The event is hosted by BioPharma Nexus, a premier company organizing top-notch conferences that develop and strengthen ties between pharmaceutical and biotech companies, along with the service providers. They strive to offer the best-quality healthcare and medication to patients all over the…

Read More>>

To know more, please visit https://ibn.fm/22ZJE.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

NRx Pharmaceuticals (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The company’s lead program NRX-101, an oral, fixed-dose combination of D-cycloserine (“DCS”) and lurasidone, targets the brain’s N-methyl-D-aspartate (“NMDA”) receptor and is being investigated in a Phase 2b/3 clinical trial for suicidal treatment-resistant bipolar depression (S-TRBD), which includes patients with both acute and sub-acute suicidality, an indication for which the only approved treatment is electroshock therapy. The company has partnered with Alvogen Pharmaceuticals for the worldwide rights to NRX-101 for treatment of S-TRBD, to help bring NRX-101 to a global population of patients with unmet this medical need. NRx Pharmaceuticals is also currently exploring NRX-101’s potential to act as a non-opioid chronic pain treatment option and awaits results from a 200 patient Department of Defense funded study of DCS in low back pain. For more information, visit the company’s website at: www.NRxPharma.com.

To view IBN’s virtual coverage of the conference, visit https://ibn.fm/DawsonJamesConference2023  

About InvestorBrandNetwork’s Virtual Coverage

The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating at the Dawson James Small Cap Growth Conference. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.

For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

MetAlert (OTC: MLRT), a pioneer in GPS wearable technology and global provider in the field of human and asset-tracking and recovery systems, and its wholly owned subsidiary Level 2 Security, announced its first commercial order for the game-changing GunAlert(R) firearm recovery device. The order has been received, and the device has been delivered to the customer, Ohio-based Range USA, which operates more than 40 locations across 10 states. According to the announcement, MetAlert recently acquired level 2 security, which provides motion-detection and GPS technology to detect unauthorized movement or use of firearms and other valuable mobile assets. The company is looking to expand into this space, which has exceptional resources following the announcement by the Office of Justice Programs, which is investing significantly in programs designed to reduce gun crime and community violence.

“We pioneered tracking and monitoring technology for humans with a primary goal of providing safety and peace of mind,” said MetAlert CEO Patrick Bertagna in the press release. “Level 2’s patented technology, which specializes in monitoring unauthorized use and movement of firearms and other valuable mobile assets, is a natural synergistic extension to our product line, and ethos of providing technology that supports saving lives. We are excited about receiving our first commercial order from Range USA, the nation’s leading indoor range & gun store, offering customers the best variety of name brand firearms, gear, supplies and accessories. . . . We expect to play an important role in the national conversation surrounding gun safety, and as part of that effort, we have begun providing police departments and police officers with evaluation units. We plan to work closely with law enforcement to help manage this channel and navigate access to the different federal grant programs currently available, along with working with the media to help bring attention to this game-changing technology when it comes to gun safety.”

To view the full press release, visit https://ibn.fm/7ZzYo

About MetAlert Inc.

MetAlert and its subsidiaries are engaged in designing, developing, manufacturing, distributing and licensing products, services and intellectual property in the GPS/BLE wearable technology, personal location, wandering assistive technology, and health-data collection and monitoring spaces. With more than 20 years of experience and an extensive patent portfolio, MetAlert is a leading solution provider for consumers/patients afflicted with Alzheimer’s, dementia and autism. This market represents approximately 2.9% of the world’s population. The company offers global end-to-end hardware, software and connectivity solutions, in addition to developing two-way tracking technologies, which seamlessly integrate with consumer products, enterprise and government agency applications. The company utilizes the latest in miniaturized, low-power consumption GPS, cellular, RF, NFC and BLE technologies, enabling caregivers to track and monitor patients in real-time. The company is known for its game-changing and award-winning patented GPS SmartSole(R) — think Dr. Scholl’s meets LoJack, the world’s first invisible, wearable technology tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism, and traumatic brain injury. MetAlert’s subscription-based business model is built around technology innovation with intellectual property protection. The company has international distributors servicing customers around the globe with subscribers in more than 40 countries ; the company is also a U.S. military government contractor. Other customers include public health authorities, municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers. For more information about this company, please visit www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Pinon Hill Capital, recognized as a leading force in E-Commerce investment, has launch a new Reg D offering. According to the announcement, the exclusive offering is designed to give accredited investors access to a diversified range of investment avenues within the E-Commerce sector. The company noted in the announcement that its approach involves strategic acquisitions and investment diversification while also providing investors with the tools they need to navigate the ever-evolving landscape of E-Commerce. The offering enables accredited investors to diversify their portfolios by participating in a variety of strategic investments. “In this era of vast investment opportunities, Pinon Hill Capital has emerged as a beacon of innovation and reliability,” said Pinon Hill Capital senior capital markets associate Cole Buller in the press release. “Our mission is to provide accredited investors with a unique pathway to tap into the dynamic world of E-Commerce.”

To view the full press release, visit https://ibn.fm/gd2Y7

About Pinon Hill Capital

Pinon Hill Capital is a pioneer in E-Commerce investment, delivering transformative experiences to accredited investors and changing the game. For more information about this company, please visit www.PinonHillCapital.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTC: PLTXF), the digital face of the plant-based community operating a one-stop shop for plant-based products, has completed the share exchange agreement with Veg House Holdings Inc. According to the announcement, the company closed on the agreement on Oct. 6, 2023; the company said the transaction “signifies a noteworthy stride towards solidifying our enhanced footprint within the expanding domains of plant-based lifestyle and wellness.” Based on the agreement, PlantX transferred a collection of assets in exchange for roughly 50.9% of the total issued and outstanding shares of Veg House at the time of the closing; these assets encompass wholly owned subsidiaries including Vegaste Technologies US Corp., Little West LLC, Plant Based Deli LLC and PlantX Living Inc.

Assets also include the company’s 53% ownership stake in Portfolio Coffee Inc. and 51% ownership in Eh Coffee Corp. In exchange, PlantX acquired six million shares out of the current estimated 11,778,639 outstanding shares in Veg House, resulting in a significant 50.9% ownership stake in the Cayman Islands-based entity. “By means of this share exchange agreement, funds were secured by Veg House at a post-transaction valuation of $11.778 million, based on the most recent private placement price of $1 USD per share, underlining the enduring enthusiasm for the industry and underscoring the significance of this transaction for steadfast supporters of the Canadian company,” said PlantX Life CEO Lorne Rapkin in the press release.

To view the full press release, visit https://ibn.fm/WLj92

About PlantX Life Inc.

PlantX is committed to being the digital face of the plant-based community as well as the one-stop shop for plant-based products. With its fast-growing category verticals, the company offers customers across North America more than 5,000 plant-based products. PlantX also has other brands in the PlantX portfolio, including a juice brand, a coffee company, a plant shop and brick-and-mortar grocery stores. PlantX uses its digital platform to build a community of like-minded consumers and, most importantly, to provide education. PlantX’s digital presence eliminates entry barriers for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information about this company, please visit www.PlantX.com and www.PlantX.ca.

NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Supply chain professionals, logistics experts, pharmaceutical executives, regulatory affairs specialists, technology and solutions providers, healthcare providers, investors, and government representatives, are all invited to attend the 2nd BioPharma Supply Chain & Logistics Nexus to be held in Philadelphia, PA, October 17-18, 2023. This diverse mix of attendees will get a unique platform for collaboration, knowledge sharing, and networking, ensuring a remarkable event for all those involved in the BioPharma supply chain and logistics ecosystem.

The BioPharma industry has always been a beacon of advancement and unwavering innovation, providing life-saving therapies and medicines to innumerable individuals across the globe. However, it’s important to ensure that these essential medications reach their destination in a timely manner amidst the…

Read More>>

To learn more, please visit https://ibn.fm/RHORL.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Aditxt (NASDAQ: ADTX) is an innovation activation company focused on the discovery, development and deployment of technologies that monitor and modulate the immune system. The company today announced that it will present at the 8th Annual Dawson James Conference on Thursday, Oct. 12, 2023, at the Wyndam Grand Jupiter at Harbourside Place in Jupiter, Florida. Aditxt’s Chief Executive Officer Amro Albanna will deliver the company’s presentation and conduct in-person one-on-one meetings throughout the conference.  Albanna’s presentation is slated to begin at 9 a.m. ET on Oct. 12 in Preserve Ballroom B.

To view the full press release, visit https://ibn.fm/Zo4XH

About Aditxt Inc.

Aditxt is an innovation activation company focused on the discovery, development and deployment of technologies that monitor and modulate the immune system. The company is headquartered in Richmond, Virginia, with operations in Mountain View, California, and Melville, New York. Aditxt’s mission of “Making Promising Innovations Possible, Together” is defined by its growing ecosystem of research institutions, global industry partners and shareholders who inform and inspire its mission. Aditxt’s diverse innovation portfolio includes: Adimune(TM), Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity and allergies; Adivir(TM), Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta(TM), Inc., offering convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere at their CLIA certified and CAP accredited clinical laboratory based in Richmond, Virginia. For more information, visit the company’s websites at www.Aditxt.com, www.Adimune.com and www.Pearsanta.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN